All Stories

  1. Mitochondrial DNA variability and Covid-19 in the Slovak population
  2. Association of Leukocyte, Erythrocyte, and Platelet Counts with Metabolic Syndrome and Its Components in Young Individuals without Overt Signs of Inflammation: A Cross-Sectional Study
  3. Metabolic Effects of Anti-TNF-α Treatment in Rheumatoid Arthritis
  4. In vivo Volumetric, DTI and 1H MRS Rat Brain Protocol for Monitoring Early Neurodegeneration and Efficacy of the Used Therapy
  5. Association of Atherogenic Index of Plasma with Cardiometabolic Risk Factors and Markers in Lean 14-to-20-Year-Old Individuals: A Cross-Sectional Study
  6. Association of Inflammatory and Oxidative Status Markers with Metabolic Syndrome and Its Components in 40-To-45-Year-Old Females: A Cross-Sectional Study
  7. Severe gestational diabetes mellitus in lean dams is associated with low IL-1α levels and affects the growth of the juvenile mouse offspring
  8. Association of α-Dicarbonyls and Advanced Glycation End Products with Insulin Resistance in Non-Diabetic Young Subjects: A Case-Control Study
  9. The Presence of Hyperhomocysteinemia Does Not Aggravate the Cardiometabolic Risk Imposed by Hyperuricemia in Young Individuals: A Retrospective Analysis of a Cross-Sectional Study
  10. Extracellular DNA concentrations in various aetiologies of acute kidney injury
  11. The Bright Side of Skin Autofluorescence Determination in Children and Adolescents with Newly Diagnosed Type 1 Diabetes Mellitus: A Potential Predictor of Remission?
  12. Lean insulin-resistant young adults display increased cardiometabolic risk: A retrospective cross-sectional study
  13. Long-Term Consumption of a Sugar-Sweetened Soft Drink in Combination with a Western-Type Diet Is Associated with Morphological and Molecular Changes of Taste Markers Independent of Body Weight Development in Mice
  14. The Effect of Long-Term Hypogonadism on Body Composition and Morphometry of Aged Male Wistar Rats
  15. Creatinine-Based Formulae Poorly Match in the Classification of Hypofiltration or Hyperfiltration in a General Population of Adolescents: A Retrospective Analysis of a Cross-Sectional Study
  16. A considerable proportion of metabolic syndrome–free adults from Bratislava Region, Slovakia, display an increased cardiometabolic burden
  17. Bone mineral density and oxidative stress in adolescent girls with anorexia nervosa
  18. Circulating extracellular DNA is in association with continuous metabolic syndrome score in healthy adolescents
  19. Oxidative status in plasma, urine and saliva of girls with anorexia nervosa and healthy controls: a cross-sectional study
  20. Neurodevelopmental testing of mice in the neonatal period does not affect their locomotor activity, depressive- and anxiety-like behaviour in adolescence
  21. Dynamics of salivary markers of kidney functions in acute and chronic kidney diseases
  22. Asymptomatic Hyperuricemia Associates with Cardiometabolic Risk Indicators in Overweight/Obese but Not in Lean Adolescents
  23. Sex Differences in Association of Elevated Blood Pressure with Variables Characterizing Cardiometabolic Risk in Young Subjects with or Without Metabolic Abnormalities
  24. Elevated blood pressure-associated cardiometabolic risk factors and biomarkers in 16–23 years old students with or without metabolic abnormalities
  25. Estimation of the proportion of metabolic syndrome-free subjects on high cardiometabolic risk using two continuous cardiometabolic risk scores: a cross-sectional study in 16- to 20-year-old individuals
  26. Maternal Consumption of a Diet Rich in Maillard Reaction Products Accelerates Neurodevelopment in F1 and Sex-Dependently Affects Behavioral Phenotype in F2 Rat Offspring
  27. Metabolic and Renal Effects of Dietary Advanced Glycation end Products in Pregnant Rats – A Pilot Study
  28. Markers of Oxidative Stress and Antioxidant Status in the Plasma, Urine and Saliva of Healthy Mice
  29. Glycated proteins in nutrition: Friend or foe?
  30. Gender-associated differences in the prevalence of central obesity using waist circumference and waist-to-height ratio, and that of general obesity, in Slovak adults
  31. Salivary creatinine and urea are higher in an experimental model of acute but not chronic renal disease
  32. Plasma markers of oxidative status were associated with increasing continuous cardiometabolic risk scores in healthy students aged 16-20 years without central obesity
  33. Prevalence of overweight/obesity among 7-year-old children—WHO Childhood Obesity Surveillance Initiative in Slovakia, trends and differences between selected European countries
  34. Oxidative stress in the brain caused by acute kidney injury
  35. The effects of a maternal advanced glycation end product-rich diet on somatic features, reflex ontogeny and metabolic parameters of offspring mice
  36. Continuous metabolic syndrome score (siMS) enables quantification of severity of cardiometabolic affliction in individuals not presenting with metabolic syndrome
  37. Gender Differences in Cardiometabolic Risk Factors in Metabolically Healthy Normal Weight Adults with Central Obesity
  38. Ethnicity and skin autofluorescence-based risk-engines for cardiovascular disease and diabetes mellitus
  39. Improvement in asymmetric dimethylarginine and oxidative stress in patients with limb salvage after autologous mononuclear stem cell application for critical limb ischemia
  40. Association between metabolically healthy central obesity in women and levels of soluble receptor for advanced glycation end products, soluble vascular adhesion protein-1, and activity of semicarbazide-sensitive amine oxidase
  41. Variables associated with unplanned general adult ICU admission in hospitalised patients: protocol for a systematic review
  42. Vitamin D status in apparently healthy medication-free Slovaks: Association to blood pressure, body mass index, self-reported smoking status and physical activity
  43. Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study
  44. Salivary markers of kidney function — Potentials and limitations
  45. Serum carboxymethyl-lysine, a dominant advanced glycation end product, is increased in women with gestational diabetes mellitus
  46. Vitamin D Levels Decline with Rising Number of Cardiometabolic Risk Factors in Healthy Adults: Association with Adipokines, Inflammation, Oxidative Stress and Advanced Glycation Markers
  47. Presence of Cardiometabolic Risk Factors Is Not Associated with Microalbuminuria in 14-to-20-Years Old Slovak Adolescents: A Cross-Sectional, Population Study
  48. Towards an alternative testing strategy for nanomaterials used in nanomedicine: Lessons from NanoTEST
  49. Prenatal dietary load of Maillard reaction products combined with postnatal Coca-Cola drinking affects metabolic status of female Wistar rats
  50. 25-Hydroxyvitamin D and Advanced Glycation Endproducts in Healthy and Hypertensive Subjects: Are There Interactions?
  51. Chronic renal insufficiency does not induce behavioral and cognitive alteration in rats
  52. Extraskeletal Functions of Vitamin D
  53. Interplay of Vitamin D, Erythropoiesis, and the Renin-Angiotensin System
  54. Is Vitamin D Deficiency Related to Accumulation of Advanced Glycation End Products, Markers of Inflammation, and Oxidative Stress in Diabetic Subjects?
  55. A pilot study of a genetic CJD risk factor (E200K) in the general Slovak population
  56. 26. Advanced glycation end products in infant formulas
  57. Can metabolic impairments in experimental diabetes be cured with poly(amido)amine (PAMAM) G4 dendrimers? – In the search for minimizing of the adverse effects of PAMAM administration
  58. Total plasma Nε-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects
  59. Skin autofluorescence reference values from newborns to adults
  60. Neuronal Activation in the Central Nervous System of Rats in the Initial Stage of Chronic Kidney Disease-Modulatory Effects of Losartan and Moxonidine
  61. Comprehensive assessment of nephrotoxicity of intravenously administered sodium-oleate-coated ultra-small superparamagnetic iron oxide (USPIO) and titanium dioxide (TiO2) nanoparticles in rats
  62. Sex differences of oxidative stress markers in young healthy subjects are marker-specific in plasma but not in saliva
  63. Advanced Glycation End Products in Infant Formulas Do Not Contribute to Insulin Resistance Associated with Their Consumption
  64. Neuromuscular electrostimulation techniques: historical aspects and current possibilities in treatment of pain and muscle waisting
  65. Influence Of Intensive Exercise On Renal Functions (Rf) And Advanced Glycation End-Products (Ages)
  66. The Effects of Anti-Inflammatory and Anti-Angiogenic DNA Vaccination on Diabetic Nephropathy in Rats
  67. Behaviour and hormonal status in healthy rats on a diet rich in Maillard reaction products with or without solvent extractable aroma compounds
  68. Advanced Oxidation Protein Products and Advanced Glycation End Products in Children and Adolescents With Chronic Renal Insufficiency
  69. The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats
  70. Association of sVAP-1, sRAGE, and CML with lactation-induced insulin sensitivity in young non-diabetic healthy women
  71. Advanced glycation end products in myocardial reperfusion injury
  72. Metabolic syndrome is inversely related to soluble receptor for advanced glycation end products: a study in mother-infant pairs
  73. Karl Peter’s fundamental contribution to the structural organization of the kidney
  74. AT1 Receptor Antagonist Candesartan Attenuates Genomic Damage in Peripheral Blood Lymphocytes of Patients on Maintenance Hemodialysis Treatment
  75. Renal and metabolic effects of three months of decarbonated cola beverages in rats
  76. AGEs Fluorescence of Plasma, Urine and Skin Reflects Dietary Exposure to Maillard Products in Formula-fed Infants
  77. Mechanisms of Acute Uremic Encephalopathy: Early Activation of Fos and Fra-2 Gene Products in Different Nuclei/Areas of the Rat Brain
  78. Association of biochemical parameters and RAGE gene polymorphisms in healthy infants and their mothers
  79. Oxidative stress, advanced glycation end products and residual renal function in the rat model of unilateral ureteral obstruction: effects of phlogenzym and losartan
  80. Advanced Glycation End Products and Acute Myocardial Infarction
  81. Renal, vascular and cardiac fibrosis in rats exposed to passive smoking and industrial dust fibre amosite
  82. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats
  83. Testing strategies for the safety of nanoparticles used in medical applications
  84. Development of methodology for alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics. NanoTEST – EC FP7 project
  85. Neuronal activation in the CNS during different forms of acute renal failure in rats
  86. Plasma advanced glycation end products are decreased in obese children compared with lean controls
  87. Functional and Partial Morphological Regression of Established Renal Injury in the Obese Zucker Rat by Blockade of the Renin-Angiotensin System
  88. Entwicklung der Peritonealdialyse
  89. Einfluss proteolytischer Enzyme auf Advanced Glycation Endproducts (AGEs) – Mögliche klinische Implikationen?
  90. PAMAM G4 dendrimers lower high glucose but do not improve reduced survival in diabetic rats
  91. Les produits de Maillard issus de la cuisson ont-ils des effets biologiques ?
  92. Plasma Concentration and Urinary Excretion of Nɛ-(Carboxymethyl)lysine in Breast Milk- and Formula-fed Infants
  93. Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function
  94. The Selective TP Receptor Antagonist, S18886 (Terutroban), Attenuates Renal Damage in the Double Transgenic Rat Model of Hypertension
  95. Dietary advanced glycation endproducts (AGEs) and their health effects - PRO
  96. Treatment targets in renal fibrosis
  97. Renal Effects of S18886 (Terutroban), a TP Receptor Antagonist, in an Experimental Model of Type 2 Diabetes
  98. Reply
  99. Genomic Damage and Malignancy in End-Stage Renal Failure: Do Advanced Glycation End Products Contribute?
  100. Association of metabolic syndrome risk factors with selected markers of oxidative status and microinflammation in healthy omnivores and vegetarians
  101. Renal Disease in Obesity: The Need for Greater Attention
  102. Relation between Different Treatment Modalities and Genomic Damage of End-Stage Renal Failure Patients
  103. Rooibos tea (Aspalathus linearis) partially prevents oxidative stress in streptozotocin-induced diabetic rats
  104. Tissue viral DNA is associated with chronic allograft nephropathy
  105. Genetic variability in the RAGE gene: Possible implications for nutrigenetics, nutrigenomics, and understanding the susceptibility to diabetic complications
  106. Renal Effects of Oral Maillard Reaction Product Load in the Form of Bread Crusts in Healthy and Subtotally Nephrectomized Rats
  107. Increased Protein Glycation in Cirrhosis and Therapeutic Strategies to Prevent It
  108. Dietary Bread Crust Advanced Glycation End Products Bind to the Receptor for AGEs in HEK-293 Kidney Cells but Are Rapidly Excreted after Oral Administration to Healthy and Subtotally Nephrectomized Rats
  109. Reduced Circulating AGE Levels and Lower Genomic Damage in Patients Undergoing Daily versus Standard Hemodialysis
  110. Advanced Glycation End Product-Induced DNA Damage: Involvement of Angiotensin II
  111. Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis
  112. Genomic damage in chronic renal failure—potential therapeutic interventions
  113. Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis
  114. Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation
  115. Genomic damage in end-stage renal failure: Potential involvement of advanced glycation end products and carbonyl stress
  116. Die Bedeutung von Übergewicht und Adipositas für Entstehung und Verlauf renaler Erkrankungen
  117. Serum Growth Factors in Hemodialyzed Patients
  118. Functional Hyperhomocysteinemia in Healthy Vegetarians: No Association with Advanced Glycation End Products, Markers of Protein Oxidation, or Lipid Peroxidation after Correction with Vitamin B12
  119. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products
  120. Effects of a diet rich in advanced glycation end products in the rat remnant kidney model
  121. Genotoxicity of advanced glycation end products in mammalian cells
  122. Effects of dietary Nε-carboxymethyllysine on expression of the biotransformation enzyme, glutathione-S-transferase, in the rat
  123. Advanced glykation end products in patients with liver cirrhosis before and after liver transplantation
  124. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis – amelioration by liver transplantation
  125. Plasma levels of advanced glycation end products in healthy, long-term vegetarians and subjects on a western mixed diet
  126. Plasma levels of advanced glycation end products in children with renal disease
  127. Advanced glycation end products and the progressive course of renal disease
  128. Advanced glycation end products (AGEs)‐induced expression of TGF‐β1 is suppressed by a protease in the tubule cell line LLC‐PK1
  129. DNA damage of lymphocytes in experimental chronic renal failure: Beneficial effects of losartan
  130. Advanced glycation end products impair protein turnover in LLC-PK1: Amelioration by trypsin
  131. Advanced glycation end products impair protein turnover in LLC-PK1: Amelioration by trypsin
  132. DNA damage of lymphocytes in experimental chronic renal failure: Beneficial effects of losartan
  133. Circulating advanced glycation end product levels in rats rapidly increase with acute renal failure
  134. Circulating advanced glycation end product levels in rats rapidly increase with acute renal failure
  135. Advanced Glycation End Products in End-Stage Renal Disease and Their Removal
  136. Franz Volhard and Theodor Fahr: achievements and controversies in their research in renal disease and hypertension
  137. Evidence for Accumulation of Advanced Glycation End Products in Acute Renal Failure
  138. Enalapril Inhibits Growth and Proliferation of Various Tissues in Rat Normotensive Four–Sixths Kidney Ablation Nephropathy
  139. The effect of oral protease administration in the rat remnant kidney model
  140. Suppressed Activities of Cathepsins and Metalloproteinases in the Chronic Model of Puromycin Aminonucleoside Nephrosis
  141. Advanced Glycation End-Product Levels in Subtotally Nephrectomized Rats: Beneficial Effects of Angiotensin II Receptor 1 Antagonist Losartan
  142. Effective long-term inhibition of thromboxane production but not of serotonin release in patients with coronary heart disease by 30 mg/d acetylsalicylic acid dosage
  143. Mesangial cell hypertrophy induced by NH4Cl: Role of depressed activities of cathepsins due to elevated lysosomal pH
  144. High-Glucose Media Enhance the Responsiveness of Tubular Cells to Growth Promoters: Effect on Lysosomal Cathepsins and Protein Degradation
  145. Nutritional Management of the Uremic Patient
  146. Effect of Chronic Therapy with Proteolytic Enzymes on Hypertension-Induced Renal Injury in the Rat Model of Goldblatt Hypertension
  147. Inhibition of glucose uptake by 5-hydroxyindoleacetic acid in the isolated rat soleus muscle
  148. Plasma Levels of 5-Hydroxyindole-Acetic Acid in Chronic Renal Insufficiency and Their Effect on Platelet Aggregation
  149. Serotonin and Platelet Activation During Treatment with Isradipine
  150. Serotonin and Platelet Activation During Treatment with Isradipine
  151. Serotonin Metabolism in Patients with Decreased Renal Function
  152. Perturbation of baseline in HPLC analysis as the consequence of sample injection
  153. Serotonin Metabolism and Platelet Aggregation Under Antihypertensive Treatment with Nitrendipine
  154. Evaluation of various bonded-phase materials for the off-line clean-up procedure of urinary 5-hydroxyindolacetic acid prior to its determination by HPLC
  155. Dependence of the separation of some biological substances on the carbon content of C18 chemically bonded phases